At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 2, 2026 at 06:01 ET
Zymeworks secured $250 million in non-dilutive financing from Royalty Pharma through a royalty-backed note, funded by 30% of future worldwide royalties on Ziihera sales. The deal extends Zymeworks' cash runway beyond 2028 and supports share repurchases and potential acquisitions, while the company retains 70% of royalties and all milestone payments.
- Zymeworks to receive $250 million from Royalty Pharma via a non-recourse, royalty-backed note
- Repayment sourced from 30% of global tiered royalties on Ziihera sales; Zymeworks retains 70%
- Royalty Pharma's cumulative repayment capped at 1.65x by 2033 or 1.925x thereafter (~$412.5M max)
- Proceeds to fund stock repurchases, potential acquisitions, and extend cash runway beyond 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access